Digitized and data-driven, drug development is poised for a major leap forward

Drug development is on the cusp of becoming considerably faster, smarter and all-around better. That’s because a perfect storm of innovation is brewing around the combination of Big Data, wearable and ingestible sensors and monitors and, not least, AI-augmented data analytics.

So suggest the authors of an opinion piece published online May 2 in the Harvard Business Review.

“Digital technologies will allow researchers to measure the health data of clinical trial participants on a regular basis during the normal course of daily living without significantly disrupting them,” the authors wrote. “They will make it possible to more accurately assess an individual’s health as well as how the...